- Corporate
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). It focuses on products that address increasing resistance and non-response to current treatment options in the therapeutic areas of bacterial infections, fungal infections and cancer. The company uses the integrated research, development and commercial operations of its subsidiary Basilea Pharmaceutica International Ltd. to discover, develop and commercialize innovative pharmaceutical products to meet the medical needs of patients with serious and potentially life-threatening conditions.
News
Basel, Switzerland, July 20, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that its license agreement with Pfizer Inc. (NYSE: PFE) for Basilea's antifungal Cresemba (isavuconazole), which was announced on June 14, has completed and therefore will now be implemented.
more...
- Basilea receives a CHF 70 million upfront payment and is eligible for additional milestone payments of up to USD 427 million and double-digit royalties on sales
- Basilea continues to focus on establishing further partnerships for the commercialization of its anti-infectives Cresemba and Zevtera in key markets around the world
- Basilea explores partnering opportunities to further strengthen its anti-infectives and oncology R&D portfolio
more...
Basel, Switzerland, June 14, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Basilea Pharmaceutica International Ltd. (Basilea) has entered into a distribution and license agreement with Avir Pharma Inc. (Avir) for Basilea's antifungal Cresemba® (isavuconazole) and antibiotic Zevtera® (ceftobiprole) in Canada.
more...
Basel, Switzerland, June 13, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has been awarded USD 54.8 million for two additional options on its existing contract with the Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response under Contract No. HHSO100201600002C, to support the phase 3 development of ceftobiprole. The total potential funding of up to approximately USD 108 million under the contract will enable Basilea to conduct two clinical phase 3 studies to evaluate Basilea's antibiotic ceftobiprole for the treatment of Staphylococcus aureus bacteremia (bloodstream infections) and acute bacterial skin and skin structure infections. The cross-supportive studies are part of the clinical phase 3 program aiming at regulatory approval of ceftobiprole in the United States.
more...
© 2017 Basilea Pharmaceutica Ltd.
